CFA Commentary on Sunshine Biopharma, Inc. (OTCBB: SBFM)

Sunshine Biopharma, Inc. -- Targeting the Challenge of Multidrug Resistance in Breast and Lung Cancer by Developing Adva-27a


NEW YORK, NY--(Marketwire - Jul 30, 2012) - InvestorIdeas.com (www.Investorideas.com), an investor research portal specializing in sector research including biotech and pharma stocks, issues CFA commentary by Patrick J. Murphy of Murphy Analytics LLC, on Sunshine Biopharma Inc. (OTCBB: SBFM) and its lead anti-cancer compound, Adva-27a. 

To read the full report:
http://www.investorideas.com/CO/SBFM/news/2012/07301.asp

About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow InvestorIdeas.com on Twitter http://twitter.com/#!/Investorideas
Follow InvestorIdeas.com on Facebook http://www.facebook.com/Investorideas

Sign up for the free investor news and biotech stock alerts
http://www.investorideas.com/Resources/Newsletter.asp

Visit the SBFM profile http://www.investorideas.com/CO/SBFM/

Disclaimer/Disclosure: The InvestorIdeas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated InvestorIdeas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26th.

Patrick Murphy was compensated five hundred dollars for the CFA commentary article. 
BC Residents and Investor Disclaimer : Effective September 15 2008 -- all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Contact Information:

InvestorIdeas.com
800-665-0411
Source - www.Investorideas.com